GRAFAPEX (Treosulfan) Patent Expiration, LOE Window & CMS Spending

GRAFAPEX (Treosulfan) by Medexus: FDA Orange Book LOE 2032-01-21, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $3,050 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMedexus
FDA Application & PathwayN214759 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-01-21
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($3,050 intro WAC)